Qiagen to Market Genome Diagnostics’ HLA Typing Products
 
Qiagen secured commercial rights to sell reagents and software for Genome Diagnostics' sequencing based typing technology, Genome Diagnostics said this week.
 
The Dutch company has developed a proprietary strategy for typing human leukocyte antigen genes. Qiagen will have global distribution rights to the technology as of January 2007.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.